Teleflex (TFX) Stock News

Teleflex (NYSE: TFX) reported second quarter 2026 revenue from continuing operations of $570.3 million, up 28.9% year over year and 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS from continuing operations was $0.96 versus $1.54, while adjusted diluted EPS rose to $1.76 from $1.73.

The company completed the $1.5 billion cash divestiture of its OEM business, estimating $1.25 billion after-tax proceeds, and repaid a $700 million Term Loan A-2. Teleflex repurchased 1.9 million shares for $250 million in Q2 and plans a further $250 million accelerated share repurchase starting August 7, 2026, under its $1 billion authorization.

Full-year 2026 guidance for GAAP revenue growth from continuing operations was reduced to 13.4%–14.4% and pro forma adjusted constant currency growth to 3.5%–4.5%. GAAP EPS guidance was lowered to $2.54–$2.84, while adjusted EPS guidance increased to $6.90–$7.20. The company highlighted FDA BLA approval for EZPLAZ freeze-dried plasma and continued advancement of the Freesolve clinical program.

Teleflex (NYSE:TFX) has completed the previously announced divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. According to Teleflex, it expects after-tax proceeds of approximately $1.25 billion from the transaction.

The company intends to use the net proceeds to support its stated capital allocation priorities, including reducing debt by $800 million and completing its $1 billion share repurchase authorization. Teleflex said the divestiture is a key step in its transformation strategy, enhancing financial flexibility and focusing on commercial excellence in its remaining businesses. Updated 2026 financial guidance is expected when second-quarter results are reported on August 6, 2026.

Teleflex (NYSE: TFX) announced that the U.S. FDA has granted Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP), the first FDA-licensed freeze dried plasma and the company’s first biologics license for a blood component.

EZPLAZ™ FDP is indicated for transfusion in adults when plasma is required and other plasma products are not available, including uncontrolled hemorrhage, massive transfusion, liver disease, disseminated intravascular coagulation, and urgent warfarin reversal. The product uses a patented flexible plastic bag rather than glass bottles, is supplied with Sterile Water for Injection, can be stored at 2–25°C with a 12‑month shelf life, and reconstitutes in about 1–2.5 minutes. Development was supported through a Cooperative Research and Development Agreement with the Defense Health Agency’s Warfighter Protection and Acute Care team, targeting battlefield and prehospital use where traditional plasma logistics are challenging.

Teleflex (NYSE:TFX) will host a conference call to discuss its second quarter 2026 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. Investors can participate by pre-registering via a provided link to receive dial-in details or by listening to a live audio webcast on teleflex.com.

An audio replay will be available from 11:00 a.m. Eastern Time on August 6, 2026, on the Teleflex website or by phone at 1 800 770 2030 (U.S./Canada) or 1 609 800 9909 (other locations), using conference ID 69028.

Teleflex (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, effective July 1, 2026. The agreement enables Premier members, at their discretion, to access pre-negotiated pricing and terms on select Teleflex vascular access products, including short-term central venous catheters, arterial catheters, and Arrow™ EZ-IO™ intraosseous access systems.

Premier members gain access to a broad Arrow™ portfolio such as Arrowg+ard Blue Plus™ central venous catheters, ErgoPack™ complete systems, multi-lumen access catheters, and percutaneous sheath introducers, aimed at supporting evidence-based vascular access practices, standardization, workflow efficiency, and management of infection-related risks.

Teleflex (NYSE:TFX) released its 2025 Global Impact Report detailing recent Corporate Social Responsibility accomplishments and future goals. The report follows GRI, SASB and TCFD frameworks and is organized around four pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.

Highlights include a physical climate risk assessment, a 41% hazardous waste reduction, 45% gas usage reduction, and 23% scope 1 and 2 GHG emissions reduction since 2019, plus a new Global Health Equity Statement.

Teleflex (NYSE:TFX) has begun enrollment in the global, pivotal BIOMAG™‑III trial of its Freesolve™ Resorbable Magnesium Scaffold (RMS), a randomized study of 1,859 patients versus Xience™ DES across up to 120 sites worldwide.

Enrollment in the 1,861‑patient BIOMAG™‑II trial finished ahead of schedule, and four‑year BIOMAG™‑I data showed 3.5% target lesion failure with no new clinical events between years two and four.

Teleflex (NYSE: TFX) reported four‑year BIOMAG™‑I data for the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G), covering 116 patients at European centers.

No cardiac death, target‑vessel myocardial infarction, or definite/probable scaffold thrombosis were seen through four years, and target lesion failure was 3.5%, supporting favorable long‑term safety and sustained performance.

Teleflex (NYSE: TFX) priced a private offering of $500 million aggregate principal amount of 5.875% senior notes due 2032 at 100.000%. Closing is expected on June 15, 2026, subject to customary conditions. Net proceeds plus cash will redeem existing 4.625% notes due 2027.

The new notes will be guaranteed by certain wholly owned domestic subsidiaries and are offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.